Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Cancer
- Pharmaceuticals
- Biotechnology
- Therapeutic
- Disease
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 26428
License Grant
The Company hereby grants to the Licensee of the United Kingdom an exclusive license to make, have made, use and sell Product(s). Invention means patented and unpatented, patentable and un-patentable, proprietary technology related to a 2’-fluoro-2-halo substituted purine nucleoside (hereafter Technology) developed by or on behalf of SRI, that is (i) related to human health applications of the Technology or (ii) necessary for the practice of Technology for human health applications as disclosed and claimed in the Patent(s).
License Property
The agreement is to co-develop the purine-based nucleoside technology that may be effective in the treatment of leukemia and lymphoma. The lead compound of such purine-based nucleosides is known as clofarabine.
The Product(s) are Drugs effective against hematologic malignancies and solid tumors as well as other therapeutic indications, such as (but not exclusively) skin disorders and transplantation immunity. All modes of administration, particularly oral and iv., are included in these terms as are specialized formulations such as those imparting controlled-release characteristics.
Field of Use
The rights granted apply to the healthcare industry.
IPSCIO Record ID: 26130
License Grant
Under the terms of the agreement the Licensee was granted the exclusive worldwide license, excluding Japan and Southeast Asia, to make, use and sell products derived from the technology for a term expiring on the date of expiration of the last patent covered by the license. Japan and Southeast Asia were added in a subsequent agreement.
License Property
The license is to develop and market purine nucleoside analogs which may be effective in the treatment of leukemia and lymphoma. The lead compound of these purine-based nucleosides is known as Clofarabine.
IPSCIO Record ID: 3547
License Grant
The Licensor sublicensed the right to manufacture, market and distribute Clofarabine in the U.S. and Canada with respect to human cancer applications.
License Property
In 2004, Clofarabine was in pivotal Phase II Clinical Trials for the treatment of pediatric acute leukemias. Clofarabine is also in Clinical Trials in a range of hematological cancers solid tumors.
Field of Use
Clofarabine is a purine nucleoside analogue, or a small molecule, which, is believed to be effective in the treatment of leukemia. Clofarabine may also be an effective agent to treat patients with solid tumor cancers.
IPSCIO Record ID: 282944
License Grant
Licensor hereby grants to Licensee and its Affiliates a license under the Licensor Licensed IP to research, develop, make, have made, use, sell, offer for sale, import, and export the Products within the Asian Territories, within the Field. The license granted herein is exclusive within the Asian Territories without any reservation of rights by Licensor, and will remain in effect until this Agreement is terminated in accordance. For avoidance of doubt, the foregoing license shall also include the right to practice the Licensor Licensed IP to manufacture Products anywhere in the world.
License Property
Clofarabine is a purine nucleoside antimetabolite which is FDA-approved for treating relapsed or refractory acute lymphoblastic leukaemia (ALL) in children after at least two other types of treatment have failed.
Product shall mean any product, service, test, or information, including Clofarabine, which, but for the license granted herein, would infringe one or more claims of a Licensor Patent or is discovered, developed, manufactured, approved, marketed or sold using Licensor Know-How or used with Licensor Know-How.
Licensor has rights in patents and technical information relating to the development and uses of 2-flouro-2-halo substituted purine nucleosides Clofarabine.
Patent shall mean (I) patent applications filed in any country within the Asian Territories.
Field of Use
Clofarabine has been shown to be effective in vitro and in vivo against hematologic malignancies and solid tumors, as well as potentially effective for various other therapeutic indications such as autoimmune diseases and transplantation immunity.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
